Pharmaceutical Technology Ed. 186

53 Pharmaceutical Techno logy zación deben garantizar que los servicios de diagnóstico, las nuevas tecnologías vacunas y las terapias estén ampliamente disponibles a precios asequibles, y cual- quier declaración sobre el alcance de la protección debe ser precisa Referencias 1. Patentes: un elemento clave en la industria farmacéutica. Pharmaceutical Technology Edición Sudamérica 2023 - N º185 2. Gurgula O. Strategic Patenting by Pharmaceutical Companies - Should Competition Law Intervene? IIC Int Rev Ind Prop Copyr Law. 2020;51(9):1062-1085. doi: 10.1007/s40319-020-00985-0. Epub 2020 Oct 28. PMID: 33132411; PMCID: PMC7592140. 3. “Pharmaceutical Sector Inquiry – Final Report”, 8 July 2009, DG Compe- tition, European Commission, p. 130. http://ec.europa.eu/competition/ sectors/pharmaceuticals/inquiry/staff_working_paper_part1.pdf 4. Bansal, Inderjit Singh & Sahu, Deeptymaya & Bakshi, Gautam & Singh, Sukhjeet. (2009). Evergreening–A Controversial Issue in Pharma Milieu. Journal of Intellectual Property Rights. 14. 299-306. 5. Nicoleta Tuominen. Patenting Strategies of the EU Pharmaceutical Indus- try – Crossroad between Patent Law and Competition Policy. Research Paper in Law Cahiers juridiques No 1 / 2011 (www.coleurope.eu ) 6. Ndubuisi, Gideon Onyewuchi, Strategic Patenting in the Pharmaceutical Industry (February 15, 2015). Available at SSRN: https://ssrn.com/abs- tract=2634889 or http://dx.doi.org/10.2139/ssrn.2634889 7. https://geneva-network.com/research/why-pharmaceutical-follow-on- innovation-should-be-eligible-for-patent-protection/ 8. Christopher M. Holman, Timo Minssen, And Eric M. Solovy. Patentability Standards for Follow-On Pharmaceutical Innovation. 37 Biotechnology Law Report 131 Number 3, 2018. 9. https://www.alston.com/-/media/files/insights/publications/2005/05/ strategies-for-extending-the-life-of-patents/files/biopharm-spruill- may2005/fileattachment/biopharm-spruill-may2005.pdf 10. Gupta H, Kumar S, Roy SK, Gaud RS. Patent protection strategies. J Pharm Bioallied Sci. 2010 Jan;2(1):2-7. doi: 10.4103/0975-7406.62694. PMID: 21814422; PMCID: PMC3146086. 11. Kapczynski A, Park C, Sampat B. Polymorphs and Prodrugs and Salts (Oh My!): An Empirical Analysis of “Secondary” Pharmaceutical Patents. PLOS One. 2012; 7. 12. https://network.febs.org/posts/drug-repurposing-that-stands-out-from- the-crowd 13. Agranat I, Marom H. In Defense of Secondary Pharmaceutical Patents in Drug Discovery and Development. ACS Med Chem Lett. 2020 Feb 13;11(2):91-98. doi: 10.1021/acsmedchemlett.9b00497. PMID: 32280427; PMCID: PMC7106985. EDICIONES VR - AULA VIRTUAL